TALPHERA, INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
TALPHERA, INC. (TLPH) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$10.29 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2024-03-06
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-12-31 was -$4.50M.
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-09-30 was -$1.42M.
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-06-30 was -$4.43M, a 106.63% decline year-over-year.
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-03-31 was $64.00K.
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was -$10.29M, a 119.15% decline from fiscal 2022.
- TALPHERA, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was $53.71M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$5.92M derived: sum of 2 quarters · filed 2024-03-06 | -$10.35M derived: sum of 3 quarters · filed 2024-03-06 | -$10.29M 10-K · filed 2024-03-06 |
| 2023-09-30 | -$1.42M 10-Q · filed 2023-11-14 | -$5.85M derived: sum of 2 quarters · filed 2023-11-14 | -$5.78M 10-Q · filed 2023-11-14 | -$10.97M derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-06-30 | -$4.43M 10-Q · filed 2023-08-10 | -$4.36M 10-Q · filed 2023-08-10 | -$9.55M derived: sum of 3 quarters · filed 2024-03-06 | -$14.38M derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-03-31 | $64.00K derived: 10-K 12 month − 3 quarters · filed 2024-03-06 | -$5.12M derived: sum of 2 quarters · filed 2024-03-06 | -$9.95M derived: sum of 3 quarters · filed 2024-03-06 | $56.86M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-12-31 | -$5.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$10.01M derived: sum of 2 quarters · filed 2024-03-06 | $56.79M derived: sum of 3 quarters · filed 2024-03-06 | $53.71M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$4.83M 10-Q · filed 2023-11-14 | $61.98M derived: sum of 2 quarters · filed 2023-11-14 | $58.90M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $66.81M 10-Q · filed 2023-08-10 | $63.08M 10-Q · filed 2023-08-10 | ||
| 2021-12-31 | -$17.15M 8-K · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |